Rating History for Eli Lilly (LLY) by Barclays
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 2/19/2026 | Carter Could | New Coverage | Overweight (N/A) |
1,350.00 (N/A) |
1020.56 (990.33) |
-2.96% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 2/19/2026 | Carter Could | New Coverage | Overweight (N/A) |
1,350.00 (N/A) |
1020.56 (990.33) |
-2.96% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||